Clearside Biomedical Inc
NASDAQ:CLSD
Clearside Biomedical Inc
Revenue
Clearside Biomedical Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Clearside Biomedical Inc
NASDAQ:CLSD
|
Revenue
$8.2m
|
CAGR 3-Years
1%
|
CAGR 5-Years
207%
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$81.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$45.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$58.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
1%
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$61.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$34.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
4%
|
Clearside Biomedical Inc
Revenue Breakdown
Breakdown by Geography
Clearside Biomedical Inc
Breakdown by Segments
Clearside Biomedical Inc
Total Revenue:
8.2m
USD
|
License:
8.2m
USD
|
See Also
What is Clearside Biomedical Inc's Revenue?
Revenue
8.2m
USD
Based on the financial report for Dec 31, 2023, Clearside Biomedical Inc's Revenue amounts to 8.2m USD.
What is Clearside Biomedical Inc's Revenue growth rate?
Revenue CAGR 5Y
207%
Over the last year, the Revenue growth was 518%. The average annual Revenue growth rates for Clearside Biomedical Inc have been 1% over the past three years , 207% over the past five years .